Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1

Trial Profile

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Ceritinib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms SIGNATURE
  • Sponsors Novartis
  • Most Recent Events

    • 27 Nov 2016 Status changed from recruiting to completed.
    • 20 Sep 2016 Planned End Date changed from 1 Sep 2018 to 1 Mar 2018.
    • 20 Sep 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top